Key Players in Japan Celiac Disease Market | Competitive Landscape 2026

Japan Celiac Disease Market Overview

According to 6Wresearch, the Japan celiac disease market is expanding steadily, supported by an increase in clinical diagnoses of non-tropical sprue and dermatitis herpetiformis. supported by a significant rise in the clinical diagnosis of non-tropical sprue and dermatitis herpetiformis. The growth is intrinsically linked to the "Westernization" of the Japanese diet and improved primary-care screening protocols that utilize high-fidelity serological testing.

Furthermore, with no FDA or PMDA-approved pharmacological cure currently on the market, domestic focus is intensifying on late-stage pipeline therapies including transglutaminase 2 (TG2) inhibitors and immune-tolerance inducing biologics.

Competitive Landscape

The competitive landscape of the Japan celiac disease market is defined by a strategic balance between established global pharmaceutical giants and domestic powerhouse firms focused on gastrointestinal health. Regulatory compliance with the Pharmaceuticals and Medical Devices Agency (PMDA) remains a vital success factor, particularly for companies conducting multi-regional clinical trials to introduce first-in-class treatments to the Japanese archipelago.

Below is a list of leading players operating in the Japan Celiac Disease Market:

1. Takeda Pharmaceutical Company Limited

A leader in celiac research, Takeda is advancing high-potential pipeline drugs like TAK-101 (immune-modifying nanoparticles) and TAK-062 (a gluten-degrading enzyme) through global clinical frameworks.

2. Chugai Pharmaceutical Co., Ltd. (Roche Group)

Utilizing its proprietary antibody engineering technologies, Chugai is highly active in the development of new biological treatments for autoimmune gastrointestinal conditions.

3. Pfizer Inc.

Deeply involved in celiac disease therapeutic research, Pfizer leverages its massive R&D infrastructure to explore drug development targets that mitigate the autoimmune inflammatory response.

4. Sanofi

Active in the clinical pipeline for celiac disease therapies, Sanofi focuses on immunological solutions that aim to protect the intestinal lining from gluten-induced damage.

5. Immunic Therapeutics

Developing promising oral small-molecule therapeutics, such as IMU-856, which is designed to restore intestinal barrier function and maintain mucosal integrity in patients.

6. Dr. Falk Pharma GmbH

A gastroenterology specialist focusing on pivotal therapeutics like ZED1227, a first-in-class small molecule transglutaminase inhibitor currently in Phase 2 clinical trials.

7. Zedira GmbH

Specializes in the discovery of transglutaminase 2 (TG2) inhibitors, providing the foundational chemistry for various celiac treatments aimed at blocking the cross-linking of gluten peptides.

8. Anokion SA

Active in developing antigen-specific immune-modifying therapies like KAN-101, which aims to re-educate the immune system to tolerate gluten.

9. Barinthus Biotherapeutics

Formerly known as Vaccitech, this company is developing novel T-cell immunotherapies designed to induce gluten-specific tolerance and prevent autoimmune flare-ups.

10. ImmunogenX

A clinical-stage biotherapeutics firm focused on the development of Latiglutenase and CypCel, a diagnostic tool for monitoring intestinal health in celiac patients.

11. Eisai Co., Ltd.

A domestic giant that provides essential gastrointestinal supportive care and diagnostic networks to improve the quality of life for Japanese patients with chronic digestive disorders.